Literature DB >> 1907306

Restricted T cell expression of IL-2/IFN-gamma mRNA in human inflammatory disease.

S A Brod1, D Benjamin, D A Hafler.   

Abstract

It has been difficult to demonstrate functionally distinct T cell populations in humans on the basis of cytokine secretion. As previous investigators have examined the T cell cytokine profile from immunized animals, we examined whether Th1 or Th2 type T cells could be identified in the peripheral blood or cerebrospinal fluid (CSF) immune compartments from subjects with or without inflammatory diseases. Using limiting dilution analysis and growth with PHA and IL-2/IL-4, we directly cloned a total of 177 T cells from the peripheral blood and CSF of seven subjects, four with inflammatory disease and three control subjects, and examined the cytokine message profile after stimulation with ionomycin and PMA. We found that most clones from both the peripheral blood and CSF express IL-1, IL-2, IL-4, IFN-gamma, or TNF-alpha cytokine mRNA after activation with ionomycin and PMA. All T cell clones tested produced TNF-alpha mRNA, and all but 14 produced IFN-gamma mRNA. As reported previously, Th0 cells, which produced IFN-gamma, IL-2, IL-4, and IL-5 mRNA, were found in most subjects. In striking contrast, Th1 cells, which expressed IL-2 and IFN-gamma but not IL-4 or IL-5 mRNA, were present in both peripheral blood and CSF of subjects with inflammatory disease but not found in peripheral blood or CSF of subjects without systemic inflammation. Th2 cells, expressing IL-4 and IL-5 but not IFN-gamma or IL-2 mRNA, were not found in any subject. These data present the first evidence for Th1 T cell clones in humans that may be associated with systemic inflammation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907306

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

Review 2.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

3.  IL-4 synthesis by in vivo-primed memory CD4+ T cells: II. Presence of IL-4 is not required for IL-4 synthesis in primed CD4+ T cells.

Authors:  R H DeKruyff; Y Fang; H Secrist; D T Umetsu
Journal:  J Clin Immunol       Date:  1995-03       Impact factor: 8.317

Review 4.  Evidence for Th2-type T helper cell control of allergic disease in vivo.

Authors:  D S Robinson; Q Hamid; M Jacobson; S Ying; A B Kay; S R Durham
Journal:  Springer Semin Immunopathol       Date:  1993

5.  Venom immunotherapy modulates interleukin-4 and interferon-gamma messenger RNA expression of peripheral T lymphocytes.

Authors:  H Akoum; A Tsicopoulos; H Vorng; B Wallaert; J P Dessaint; M Joseph; Q Hamid; A B Tonnel
Journal:  Immunology       Date:  1996-04       Impact factor: 7.397

6.  Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury.

Authors:  V A Maria; R M Victorino
Journal:  Gut       Date:  1997-10       Impact factor: 23.059

Review 7.  Biology of human TH1 and TH2 cells.

Authors:  S Romagnani
Journal:  J Clin Immunol       Date:  1995-05       Impact factor: 8.317

8.  Isolation and functional characterization of T cells from human sputum.

Authors:  G T Pang; R L Clancy; G E Reeves
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

9.  Dysregulated T cell expression of TIM3 in multiple sclerosis.

Authors:  Ken Koguchi; David E Anderson; Li Yang; Kevin C O'Connor; Vijay K Kuchroo; David A Hafler
Journal:  J Exp Med       Date:  2006-06-05       Impact factor: 14.307

10.  Early signaling defects in human T cells anergized by T cell presentation of autoantigen.

Authors:  J M LaSalle; P J Tolentino; G J Freeman; L M Nadler; D A Hafler
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.